Pins matching tag:GLP-1

On 5 December 2017 the US FDA approved Ozempic (semaglutide 0.5 mg and 1 mg, once weekly) for adults with type 2 diabetes, the first brand in the semaglutide line that later produced Wegovy and the Wegovy pill.

On 4 June 2021 the US FDA approved Wegovy (semaglutide 2.4 mg once weekly) for chronic weight management, the first new weight drug since 2014, with 12.4% average weight loss over placebo in adults without diabetes.

On 13 May 2022 the US FDA approved Mounjaro (tirzepatide, once weekly), the first dual GIP and GLP-1 receptor agonist, opening Eli Lilly's challenge to Novo Nordisk's semaglutide brands.

On 8 November 2023 the US FDA approved Zepbound (tirzepatide, once weekly) for chronic weight management, with 18% average weight loss at 15 mg over 72 weeks, setting up the Wegovy versus Zepbound rivalry.

On 26 November 2024 Amgen reported 52-week Phase 2 data for its monthly obesity candidate MariTide, with up to about 20% average weight loss without a plateau, and announced the MARITIME Phase 3 program.

On 13 November 2025 Pfizer completed its acquisition of obesity biotech Metsera for US$65.60 per share in cash, an enterprise value of about US$7.0 billion, plus a contingent value right of up to US$20.65 per share.

Eli Lilly's market value crossed $1 trillion on 21 November 2025, making it the first drugmaker and first health-care company to join the club dominated by tech giants. Its shares hit a record $1,066.65 and closed at $1,059.70, driven by Zepbound and Mounjaro.

On 22 December 2025 the US FDA approved the once-daily Wegovy pill (oral semaglutide 25 mg), the first oral GLP-1 for weight management, which showed 16.6% mean weight loss in the OASIS 4 trial.

The FDA approved Eli Lilly's Foundayo, a once-daily GLP-1 pill for weight loss that needs no food or water restrictions, with direct-to-consumer sales from April 6.

People on the top 12 mg dose of Lilly's triple-hormone shot retatrutide lost an average of 28.3% of their body weight (70.3 lbs) over 80 weeks, and 30.3% by two years in the extension - weight loss at the level of bariatric surgery.

On 4 August 2026 Novo Nordisk reported Q2 adjusted sales up 7% and adjusted operating profit up 11% at constant exchange rates and raised its 2026 outlook to 0% to -6%, helped by stronger GLP-1 sales.

A 236-acre plant that will make the active ingredient of Lilly's Foundayo weight-loss pill, with more than 600 permanent jobs and about 4,000 construction jobs. Lilly expects it running by 2030.

Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.